Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab for Lupus Nephritis Induction
NCT04702256Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2021
- Primary completion
- Dec 2031
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of obinutuzumab in lupus nephritis (LN), sponsored by Assistance publique - Hôpitaux de Paris. Started Dec 2021; status: recruiting.
02
Drugs
obinutuzumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT04702256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04702256.